Prague, Czechia

Tomas Jandusik

USPTO Granted Patents = 2 

 

 

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2021

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations of Tomas Jandusik

Introduction

Tomas Jandusik is a notable inventor based in Prague, Czech Republic. He has made significant contributions to the field of organic chemistry and biochemistry, particularly in the development of novel compounds that have potential therapeutic applications.

Latest Patents

Jandusik holds two patents that focus on cyclic dinucleotides with phosphonate bonds. The first patent, titled "2'3′ cyclic dinucleotides with phosphonate bond activating the STING adaptor protein," describes compounds that can be used for the treatment or prevention of diseases modifiable by STING protein modulation, such as cancer and various viral, allergic, and inflammatory diseases. These compounds may also serve as adjuvants in vaccines. The second patent, "3'3′ cyclic dinucleotides with phosphonate bond activating the STING adaptor protein," similarly outlines the use of these cyclic phosphonate dinucleotides for therapeutic purposes, emphasizing their pharmaceutical compositions and potential applications in medicine.

Career Highlights

Tomas Jandusik is affiliated with the Institute of Organic Chemistry and Biochemistry, where he conducts research and develops innovative solutions in his field. His work has garnered attention for its potential impact on medical treatments and vaccine development.

Collaborations

Jandusik collaborates with esteemed colleagues, including Gabriel Birkus and Ondrej Pav, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Tomas Jandusik's work exemplifies the intersection of chemistry and medicine, showcasing how innovative inventions can lead to advancements in healthcare. His patents reflect a commitment to addressing significant health challenges through scientific research and collaboration.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…